Christian Klein

PD

Ludwig-Maximilians-Universität München
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (62)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

T-Cell Engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in scRNA-seq technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment (TME). In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (PBMC) from glofitamab-treated R/R B-NHL patients, achieving complete metabolic responders (CMR) or progressive metabolic disease (PMD). Our findings reveal that the maintenance of naive-like ("fresher") T-cell states (particularly the fresher cytotoxic T cells) at early timepoints is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared to non-responders. Furthermore, the analysis of patient PBMCs and intra-tumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB co-stimulation translated into increased proportions of intra-tumor T cells having a "fresher", naive-like phenotype, ultimately leading to stronger anti-tumor efficacy. Taken together, our findings underscore the therapeutic relevance of "fresher" naive-like T-cell states and the potential of leveraging 4-1BB co-stimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (30)

Nicola Ternette

Professor

University of Dundee

UNITED KINGDOM
View details

Jennifer Gommerman

Full Professor

University of Toronto

CANADA
View details

Luciano A Masullo

Project Leader

Max Planck Institute of Biochemistry

GERMANY
View details

Thomas Nerreter

University Hospital Würzburg

GERMANY
View details

Sara Labiano

Group Leader

Center for Applied Medical Research

SPAIN
View details

Felix Luessi

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY
View details

Henry Kao

Group Head, Biomarker Sciences

-

SWITZERLAND
View details

Solange Peters

-

SWITZERLAND
View details

Roberto Villaseñor

Lab Head

F Hoffmann-La Roche AG

SWITZERLAND
View details

Anthony J. Saviola

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Yuwen Zhu

Professor with tenure

University of Colorado School of Medicine

UNITED STATES
View details

Anne‐Katrin Pröbstel

-

SWITZERLAND
View details

Pilar Garrido López

Head Medical Oncology Department

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

SPAIN
View details

David John

Goethe University Frankfurt

GERMANY
View details

Christian Münz

University of Zurich

SWITZERLAND
View details

Jessica Hartmann

Senior Researcher and Regulatory Assessor

Paul-Ehrlich-Institut

GERMANY
View details

Alfred Zippelius

University of Basel

SWITZERLAND
View details

Ralf Jungmann

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Andrés Cervantes

Professor of Medicine

University of Valencia

SPAIN
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Viktor Koelzer

Medical Co-Director, Professor of Experimental Pathology

University of Zurich

SWITZERLAND
View details

Sana D. Karam

Professor and Department Chair

Washington University in St. Louis

UNITED STATES
View details

Michael Thomas Sandholzer

University of Basel

SWITZERLAND
View details

Joanna Kalucka

Assistant Professor

Aarhus University

DENMARK
View details

Kristoffer Rohrberg

Ass. Professor

Faculty of Health and Medical Sciences, University of Copenhagen

DENMARK
View details

Heinz Läubli

University of Basel

SWITZERLAND
View details

Frauke Zipp

Head of Department

Johannes Gutenberg Universität Universitätsmedizin

GERMANY
View details

Sara Colombetti

Global Head of Oncology Discovery Pharmacology

Roche Diagnostics

SWITZERLAND
View details

Nicole Joller

Professor for Immunology

University of Zurich

SWITZERLAND
View details